Melane Sampson, Author at BioTuesdays

Feature

Cardiol Therapeutics Advancing Life-Changing Therapies for Heart Disease, Showing Potential to Reverse Inflammation-Driven Structural Damage

Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) is emerging as a leader in the development of anti-inflammatory and anti-fibrotic medicines designed to counteract the fundamental biological processes that drive...

December 2, 2025

Developments

Actinium reports ATNM-400 data showing potent efficacy in TNBC

Actinium Pharmaceuticals (NYSE American: ATNM) has announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) antibody radioconjugate, in hormone receptor positive (HR+), HER2 positive...

December 1, 2025

Executive Moves

Cadrenal appoints Dr. Lee Golden to BOD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced the appointment of Lee Scott Golden, MD, to its board of directors (BOD) as an independent director, effective immediately. Dr. Golden currently serves as EVP and CMO...

December 1, 2025

Executive Moves

Dr. Mark Jaroszeski joins Aspire’s scientific team

Aspire Biopharma (NASDAQ: ASBP) has announced the addition of tenured professor, department of medical engineering, University of South Florida, Mark J. Jaroszeski, PhD, to its scientific team. Dr. Jaroszeski is a...

November 26, 2025

Developments

BiomX reports update on trial of BX004 in CF

BiomX (NYSE American: PHGE) has announced that the FDA is continuing its evaluation of the nebulizer device used for drug administration in the company’s Phase 2b trial of BX004 in patients with cystic fibrosis (CF)...

November 26, 2025

Developments

Ripple enters into a collaboration with Bausch + Lomb

Closely held Ripple Therapeutics has announced that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb (NYSE/TSX: BLCO). Under the terms of the...

November 25, 2025

Developments

Clearmind’s DSMB recommends continuation of trial for CMND-100 in AUD; patient enrollment at TASMC kicks off

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that its independent Data and Safety Monitoring Board (DSMB) has completed a scheduled interim review of its ongoing FDA-approved multinational Phase I/IIa...

November 25, 2025

Developments

PetVivo launches AI platform reducing vet client acquisition costs by 50-89%

PetVivo Holdings (OTCQX: PETV; OTCID: PETVW) has announced the launch of PetVivo.ai that delivers a veterinary client acquisition cost of $42.53—a 50% to 89% reduction compared to $80 to $400 typically spent by...

November 25, 2025

Feature

Trevi reinventing chronic cough treatment with a dual-action approach to hypersensitivity

Trevi Therapeutics (NASDAQ: TRVI) is advancing a fundamentally different approach to the treatment of chronic cough—a high unmet need that significantly affects the quality of life for millions of Americans.

November 25, 2025

Developments

Psyence reports major breakthrough in establishing pharmaceutical-grade ibogaine supply

Psyence BioMedical (NASDAQ: BPM) has announced it has sourced a sustainable supply of high-potency iboga bark—through its strategic partner, closely held PsyLabs—a significant achievement as the company prepares for the...

November 20, 2025

Author - Melane Sampson

Cardiol Therapeutics Advancing Life-Changing Therapies for Heart Disease, Showing Potential to Reverse Inflammation-Driven Structural Damage

Actinium reports ATNM-400 data showing potent efficacy in TNBC

Cadrenal appoints Dr. Lee Golden to BOD

Dr. Mark Jaroszeski joins Aspire’s scientific team

BiomX reports update on trial of BX004 in CF

Ripple enters into a collaboration with Bausch + Lomb

Clearmind’s DSMB recommends continuation of trial for CMND-100 in AUD; patient enrollment at TASMC kicks off

PetVivo launches AI platform reducing vet client acquisition costs by 50-89%

Trevi reinventing chronic cough treatment with a dual-action approach to hypersensitivity

Psyence reports major breakthrough in establishing pharmaceutical-grade ibogaine supply

Subscribe